DOD Proposes Substantial Revision to Intellectual Property Rules
Client Alert | less than 1 min read | 09.29.10
On September 27, 2010, the DoD published a proposed rule which would substantially revise the DFARS Part 227 rules and the associated clauses relating to Intellectual Property. There are numerous proposed changes which collectively are a mixed bag, but perhaps the most problematic change relates to the treatment of commercial technical data and commercial computer software, which includes a caveat that any government funding eliminates the commercial item nature of the product.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
